What Jazz Pharmaceuticals plc told the SEC could break it.

Jazz believes it is the sole worldwide producer of defibrotide API, made from porcine DNA in a single facility in Villa Guardia, Italy — a single-site dependency for Defitelio.

“We are our own sole supplier of, and we believe that we are currently the sole worldwide producer of, defibrotide API. We manufacture defibrotide API from porcine DNA in a single facility located in Villa Guardia, Italy.”

The API for Jazz's flagship oxybate products (Xywav/Xyrem) is made by a single-source supplier; Jazz depends on single-source suppliers for most products and their APIs.

“We depend on single source suppliers for most of our products, product candidates and their APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.”

As an Irish-domiciled company importing products into its largest (U.S.) market, Jazz is exposed to potential new and increased tariffs on pharmaceutical and biological products.

“and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, and could continue to significantly increase tariffs on a broad array of goods, including pharmaceutical and biological products.”

The Inflation Reduction Act replaced the Part D coverage-gap discount program with a manufacturer discount program requiring 10% discounts in the initial phase and 20% in the catastrophic phase, pressuring Jazz's net drug pricing.

“The IRA ended the coverage gap discount program, under which manufacturers agreed to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during the coverage gap period, starting in 2025 and replaced it with a new manufacturer discount program, under which manufacturers are, in general, required to provide a 10% discount on a covered Part D drug where a beneficiary is in the initial phase of Part D coverage and a 20% discount where a beneficiary is in the catastrophic phase of Part D coverage.”

Jazz's receivables are highly concentrated in a few specialty distributors — five customers were 80% of gross AR, led by ESSDS (39%), ASD (15%) and McKesson (13%).

“As of December 31, 2024, five customers accounted for 80 % of gross accounts receivable, including ESSDS, which accounted for 39 % of gross accounts receivable, ASD, which accounted for 15 % of gross accounts receivable and McKesson, which accounted for 13 % of gross accounts receivable.”

Jazz derives the majority of revenue from the U.S. but manufactures key products abroad — Xywav/Xyrem in Athlone, Ireland, plus facilities in Kent, U.K. and Villa Guardia, Italy — exposing it to cross-border supply and trade risk.

“While we are an Irish company headquartered in Dublin, Ireland, we derive the majority of our revenues from sales of our products in the U.S. We conduct business globally and our operations, including third-party suppliers, span numerous countries outside the U.S. In particular, we have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing and development facility in Kent Science Park, U.K.”